Einhorn LM, Zhan M, Hsu VD et al (2009) The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169:1156–1162

Article  PubMed  PubMed Central  Google Scholar 

Sarnowski A, Gama RM, Dawson A et al (2022) Hyperkalemia in chronic kidney disease: links, risks and management. Int J Nephrol Renovasc Dis 15:215–228

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clase CM, CarreroJJ EDH et al (2020) Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kid Kidney Int 97:42–61

Article  CAS  Google Scholar 

Larivée NL, Michaud JB, More KM et al (2023) Hyperkalemia: prevalence. Predict Emerg Treat Cardiol Ther 12(1):35–63

Google Scholar 

Maschio G, Alberti D, Janin G et al (1996) The Angiotensin converting-enzyme inhibition in progressive renal insufficiency study group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Eng J Med 334:939–945

Article  CAS  Google Scholar 

The GISEN Group (Gruppo Italiano di Studi Epidemiologici In Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857–1863

Article  Google Scholar 

Cheung AK, Chang TI, Cushman WC et al (2019) Blood pressure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 95:1027–1036

Article  PubMed  Google Scholar 

Kidney Disease Improving Global Outcome (KDIGO) Working Group (2012) KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2:337–414

Google Scholar 

Taler SJ, Agarwal R, Bakris GL et al (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 62:201–213

Article  PubMed  PubMed Central  Google Scholar 

Capuano I, Buonanno P, Riccio E et al (2022) Randomized controlled trials on renin angiotensin aldosterone system inhibitors in chronic kidney disease stages 3–5: are they robust? a fragility index analysis. J Clin Med 11(20):6184

Article  CAS  PubMed  PubMed Central  Google Scholar 

Epstein M, Reaven NL, Funk SE et al (2015) Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 21:S212-220

PubMed  Google Scholar 

Yildirim T, Arici M, Piskinpasa S et al (2012) Major barriers against renin–angiotensin–aldosterone system blocker use in chronic kidney disease stages 3–5 in clinical practice: a safety concern? Ren Fail 34:1095–1099

Article  CAS  PubMed  Google Scholar 

McCullogh PA, Rangaswami J (2018) Real or perceived: hyperkalemia is a major deterrent for renin-angiotensin aldosterone system inhibition in heart failure. Nephron 138:173–175

Article  Google Scholar 

Riccio E, Capuano I, Buonanno P et al (2022) RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study. Front Cardiovasc Med 9:824095

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palmer BF (2004) Managing hyperkalemia caused by inhibitors of the renin–angiotensin–aldosterone system. N Engl J Med 351:585–592

Article  CAS  PubMed  Google Scholar 

Sterns RH, Rojas M, Bernstein P, Chennupati S (2010) Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 21:733–735

Article  CAS  PubMed  Google Scholar 

Harel Z, Harel S, Shah PS et al (2013) Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 126(3):264.e9-264.e24

Article  CAS  PubMed  Google Scholar 

Buysse JM, Huang IZ, Pitt B (2012) PEARL HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Futur Cardiol 8:17–28

Article  CAS  Google Scholar 

Agarwal R, Rossignol P, Romero A (2019) Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394(10208):1540–1550

Article  CAS  PubMed  Google Scholar 

St-Jules DE, Fouque D (2022) Etiology-based dietary approach for managing hyperkalemia in people with chronic kidney disease. Nutr Rev 80(11):2198–2205

Article  PubMed  Google Scholar 

Hinderling PH (2016) The pharmacokinetics of potassium in humans is unusual. J Clin Pharmacol 56(10):1212–1220

Article  CAS  PubMed  Google Scholar 

Kovesdy CP, Gosmanova EO, Woods SD et al (2020) Real-world management of hyperkalemia with patiromer among United States Veterans. Postgrad Med 132(2):176–183

Article  PubMed  Google Scholar 

Pecoits-Filho R, McCullough K, Muenz D et al (2022) Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany. Clin Kidney J 16(1):176–183

Article  PubMed  PubMed Central  Google Scholar 

Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612

Article  PubMed  PubMed Central  Google Scholar 

Bakris GL, Pitt B, Weir MR et al (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial AMETHYST-DN. Invest JAMA 314(2):151–161

Article  CAS  Google Scholar 

Weir MR, Bakris GL, Bushinsky DA, OPAL-HK Investigators et al (2015) Investigators patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372(3):211–221

Article  PubMed  Google Scholar 

Pitt B, Bakris GL, Bushinsky DA et al (2015) Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 17:1057–1065

Article  CAS  PubMed  Google Scholar 

Pitt B, Bakris GL, Weir MR et al (2018) Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail 5:592

Article  PubMed  PubMed Central  Google Scholar 

Drieling RL, LaCroix AZ, Beresford SA et al (2016) Validity of self-reported medication use compared with pharmacy records in a cohort of older women: findings from the women’s health initiative. Am J Epidemiol 184:233–238

Article  PubMed  PubMed Central  Google Scholar 

Pecoits-Filho R, Fliser D, Tu C et al (2019) Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. J Clin Hypertens (Greenwich) 21:991–1001

Article  PubMed  Google Scholar 

Sabbatini M, Garofalo G, Borrelli S et al (2014) Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Prefer Adherence 8:73–81

Article  PubMed  PubMed Central  Google Scholar 

te Dorsthorst RPM, Hendrikse J, Vervoorn MT et al (2019) Review of case reports on hyperkalemia induced by dietary intake: not restricted to chronic kidney disease patients. Eur J Clin Nutr 73(1):38–45

Article  Google Scholar 

Ramos CI, González-Ortiz A, Espinosa-Cuevas A et al (2021) Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? Nephrol Dial Transplant 36(11):2049–2057

Article  CAS  PubMed  Google Scholar